Last reviewed · How we verify
ferric(III)carboxymaltose
Ferric carboxymaltose is an iron replacement therapy that delivers ferric iron complexed with carboxymaltose to replenish depleted iron stores and treat iron deficiency anemia.
Ferric carboxymaltose is an iron replacement therapy that delivers ferric iron complexed with carboxymaltose to replenish depleted iron stores and treat iron deficiency anemia. Used for Iron deficiency anemia in adults, Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in patients intolerant to or with inadequate response to oral iron.
At a glance
| Generic name | ferric(III)carboxymaltose |
|---|---|
| Also known as | Ferinject |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Drug class | Iron replacement agent |
| Target | Iron metabolism / transferrin-mediated iron transport |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
The carboxymaltose ligand stabilizes ferric iron in a form that can be safely administered intravenously, allowing rapid iron delivery without the gastrointestinal side effects of oral iron. The iron is taken up by transferrin and incorporated into hemoglobin and iron-storage proteins to restore oxygen-carrying capacity and correct anemia.
Approved indications
- Iron deficiency anemia in adults
- Iron deficiency anemia in patients with chronic kidney disease
- Iron deficiency anemia in patients intolerant to or with inadequate response to oral iron
Common side effects
- Injection site reactions
- Headache
- Nausea
- Dizziness
- Hypophosphatemia
Key clinical trials
- Hypoferritinemia Without Anemia Among Reproductive Age Females (NA)
- Comparison of the Rate of Preoperative Haemoglobin After Administration of Epoetin Alpha Associated With an Oral Medical Supplementation Versus Intravenous Before Surgery of Craniosynostosis at the Child (NA)
- Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial (PHASE3)
- Effect of Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation (PHASE3)
- A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA) (PHASE3)
- Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF) (PHASE3)
- Treatment of Anemia With Intravenous Iron in Patients Listed for Orthotopic Liver Transplantation (PHASE4)
- Preoperative Intravenous Iron to Treat Anaemia in Major Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: